感染

订阅

MedSci主页 / 所有栏目 / 感染

HIV病毒抑制剂PRO 140的研究

2018-06-24 MedSci MedSci原创

PRO140HIV病毒CCR5单克隆抗体
关注

PRO 140是CytoDyn公司开发的一种新型人源化CCR5单克隆抗体。在PRO 140与现有ART一起皮下注射一周后，病人的平均病毒载量从平均基线病毒载量下降约97％。该试验达到了其主要疗效终点：在一周治疗期结束时，HIV-1 RNA病毒载量降低显著。

PRO 140是CytoDyn公司开发的一种新型人源化CCR5单克隆抗体。在PRO 140与现有ART一起皮下注射一周后，病人的平均病毒载量从平均基线病毒载量下降约97％。该试验达到了其主要疗效终点：在一周治疗期结束时，HIV-1 RNA病毒载量降低显著。

一项新的艾滋病毒治疗PRO 140的关键性试验结果显示，PRO 140是一种有效的长效治疗药物，与抗逆转录病毒治疗（ART）相结合可有效降低病毒载量。这是一项正在进行的随机，双盲，安慰剂对照试验。CytoDyn总裁兼首席执行官Nader Pourhassan博士表示：“尽管多年来ART已经大幅改善患者病情，但需要新药来提高药效和药代动力学曲线、降低毒性、防止药物耐药性，并提高便利性以促进患者依从性。这些试验结果支持了PRO 140的持续发展，它是一种简单易行，长效的HIV-1治疗方法，与ART一起可以为耐药的患者提供有价值的治疗选择”。


原始出处：

https://www.europeanpharmaceuticalreview.com/news/76359/weekly-injections-hiv-1-suppression/

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007025, encodeId=ccd8200e025c1, content=<a href='/topic/show?id=9d62e0946c6' target=_blank style='color:#2F92EE;'>#病毒抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70946, encryptionId=9d62e0946c6, topicName=病毒抑制)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri Jul 13 21:11:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851740, encodeId=05e61851e409e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 01 18:11:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957093, encodeId=776a195e09318, content=<a href='/topic/show?id=a8d5e09475e' target=_blank style='color:#2F92EE;'>#病毒抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70947, encryptionId=a8d5e09475e, topicName=病毒抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 20 23:11:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412639, encodeId=54b81412639ae, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602021, encodeId=2ac21602021f0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-07-13 siiner

    #病毒抑制#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2007025, encodeId=ccd8200e025c1, content=<a href='/topic/show?id=9d62e0946c6' target=_blank style='color:#2F92EE;'>#病毒抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70946, encryptionId=9d62e0946c6, topicName=病毒抑制)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri Jul 13 21:11:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851740, encodeId=05e61851e409e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 01 18:11:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957093, encodeId=776a195e09318, content=<a href='/topic/show?id=a8d5e09475e' target=_blank style='color:#2F92EE;'>#病毒抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70947, encryptionId=a8d5e09475e, topicName=病毒抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 20 23:11:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412639, encodeId=54b81412639ae, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602021, encodeId=2ac21602021f0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-07-01 jklm09

    #抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2007025, encodeId=ccd8200e025c1, content=<a href='/topic/show?id=9d62e0946c6' target=_blank style='color:#2F92EE;'>#病毒抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70946, encryptionId=9d62e0946c6, topicName=病毒抑制)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri Jul 13 21:11:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851740, encodeId=05e61851e409e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 01 18:11:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957093, encodeId=776a195e09318, content=<a href='/topic/show?id=a8d5e09475e' target=_blank style='color:#2F92EE;'>#病毒抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70947, encryptionId=a8d5e09475e, topicName=病毒抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 20 23:11:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412639, encodeId=54b81412639ae, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602021, encodeId=2ac21602021f0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-12-20 hb2008ye

    #病毒抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2007025, encodeId=ccd8200e025c1, content=<a href='/topic/show?id=9d62e0946c6' target=_blank style='color:#2F92EE;'>#病毒抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70946, encryptionId=9d62e0946c6, topicName=病毒抑制)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri Jul 13 21:11:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851740, encodeId=05e61851e409e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 01 18:11:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957093, encodeId=776a195e09318, content=<a href='/topic/show?id=a8d5e09475e' target=_blank style='color:#2F92EE;'>#病毒抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70947, encryptionId=a8d5e09475e, topicName=病毒抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 20 23:11:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412639, encodeId=54b81412639ae, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602021, encodeId=2ac21602021f0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 tigerlr99

    #HIV病毒#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2007025, encodeId=ccd8200e025c1, content=<a href='/topic/show?id=9d62e0946c6' target=_blank style='color:#2F92EE;'>#病毒抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70946, encryptionId=9d62e0946c6, topicName=病毒抑制)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri Jul 13 21:11:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851740, encodeId=05e61851e409e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 01 18:11:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957093, encodeId=776a195e09318, content=<a href='/topic/show?id=a8d5e09475e' target=_blank style='color:#2F92EE;'>#病毒抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70947, encryptionId=a8d5e09475e, topicName=病毒抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Dec 20 23:11:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412639, encodeId=54b81412639ae, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602021, encodeId=2ac21602021f0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jun 26 09:11:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 sunylz

    #PRO#

    0

相关资讯

PRO专题：新药临床试验要尊重患者感受——Our Health,Our Care,Our Say

近年来，在临床研究中，通过测评患者对自身疾病症状及其对日常生活所造成的影响所持的态度，来决定治疗方案以及作为评价疗效的工具已经越来越普遍。临床研究领域关键人物也开始认识到了患者报告临床结局（patient reported outcome，PRO）测评日益增长的价值。2006年2月美国FDA（Food and Drug Administration）发布了关于PRO应用于新药研制和疗效评价的指南草